key: cord-0866114-3psxhm9p
authors: Buryachkovskaya, Liudmila; Lomakin, Nikita; Melkumyants, Arthur; Docenko, Julia; Serebruany, Victor
title: Tocilizumab, blood cells, and mild COVID-19: delayed vascular protection by interleukin blockade?
date: 2021-06-29
journal: Eur Heart J Cardiovasc Pharmacother
DOI: 10.1093/ehjcvp/pvab051
sha: 749793caa7f38edfbbf4bc27af1aa769b94924b0
doc_id: 866114
cord_uid: 3psxhm9p

nan

The ongoing COVID-19 pandemicand lack of proven therapeutic strategies lead to testing and regulatory approval for various existing agents, including array of monoclonal Obviously, the critical cases of COVID-19 are characterized with pronounced coagulopathy and endothelial dysfunction. [3] [4] [5] However, the validity of such association is based mostly on sporadic random clinical observations or autopsy, while precise cellular data in survivors, or the impact of anti-inflammatory agents on blood cell preservation and vascular protection, are lacking. We here utilized scanning electron microscopy assessing impact of tocilizumab on phenotype and interactions between erythrocytes, leukocytes, and platelets in hospitalized COVID-19 patients. Patients (n = 9) with PCR-confirmed COVID-19 diagnosis were admitted to the hospital from 25 May to 22 July 2020 and included in this single-centre prospective observational study. The details are outlined elsewhere. 6 Admission and discharge venous blood samples were collected for electron microscopy. The demographics and comorbidities in the COVID-19 patients match well, but not ideally probably due to small sample size. Tocilizumab 400 mg single dose subcutaneously (n = 4), or next day repeated administration for the total of 800 mg (n = 5), was compared with COVID-negative matched control patients (n = 32). During the hospital stay, all patients survived, and no patient was referred to ICU or required mechanical ventilation. The typical differences in blood cell structures before and after tocilizumab treatment are exhibited in Figure 1 . We are extremely limited in making any assumptions due to the small sample size, and different tocilizumab doses and treatment duration. Moreover, our COVID-negative controls were not ideally matched. However, there are few important advances raised by the index preliminary report. First, the in- terleukin blockade unquestionably improves erythrocyte membrane permeability, reducing echinocytosis and sludge formation. It seems that tocilizumab decreases nuclear net neutrophil construction without impacting platelet-leucocyte crosstalk. The drug definitely does not increase platelet activation, but rather stimulates their production enhancing excess young platelet circulation. In lay terms, we found no evidence that tocilizumab hurts any cellular biomarkers in COVID-positive patients. These effects were mild but either neutral or positive suggesting recovery. Second, discharge samples from COVID survivors revealed ongoing blood cell damage potentially requiring delayed protection far beyond hospitalization. Finally, long-term controlled outcome-driven trials with hard endpoints are urgently needed for exploring optimal antithrombotic and vascular protection strategies by targeting numerous inflammatory markers in general and interleukin in particular. 

Efficacy of tocilizumab in COVID-19: a systematic review and meta-analysis

Effectiveness of tocilizumab in patients hospitalized with COVID-19: a follow-up of the CORIMUNO-TOCI-1 randomized clinical trial

Thromboinflammation and the hypercoagulability of COVID-19

Endothelial cells orchestrate COVID-19 coagulopathy

Immunity, endothelial injury and complement-induced coagulopathy in COVID-19

Mild COVID-19 and Impaired Blood Cell-Endothelial Crosstalk: Considering Long-Term Use of Antithrombotics?

We are indebted to Dr Vyacheslav Golkov (Nanopromimport, Science Park in Moscow State University) and engineer Igor Bogdanov for excellent technical support. We are grateful to research nurse Irina Varyushkina for patient data collection.

Russian Foundation for Basic Research (19-015-00213 to A.M.); HeartDrug TM Research LLC (to V.S.).